Related Experiment Video

Updated: May 25, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Sorafenib for the treatment of renal cancer

Dirk Strumberg1

  • 1University of Bochum - Hematology and Oncology, Marienhospital Herne , Hölkeskampring 40, 44625 Herne , Germany. dirk.strumberg@marienhospital-herne.de

Expert Opinion on Pharmacotherapy
|January 24, 2012
PubMed
Abstract

Insights

Sorafenib, the first oral multikinase inhibitor for advanced renal cell carcinoma (RCC), shows proven efficacy and tolerability. Further research is needed to optimize sequential therapies and identify biomarkers for personalized treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Sorafenib is the first approved oral antiangiogenic multikinase inhibitor for advanced renal cell carcinoma (RCC).
  • Six drugs are now approved for RCC treatment since 2005.

Purpose of the Study:

  • Review the development of sorafenib for advanced RCC.
  • Summarize and compare its safety, tolerability, and efficacy with other RCC treatments.
  • Discuss preliminary data on sequential and combination therapies.

Main Methods:

  • Review of preclinical and clinical development of sorafenib.
  • Summary of safety, tolerability, and efficacy data.
  • Discussion of sequential and combination treatment strategies.

Main Results:

  • Sorafenib demonstrates efficacy and good tolerability in RCC patients of all ages.
  • Limited cross-resistance observed with sequential targeted drug use.
  • First-line sorafenib therapy may offer greater clinical benefits.

Conclusions:

  • Sorafenib is a well-tolerated and effective treatment for RCC.
  • Optimal sequential therapy requires further investigation in prospective trials.
  • Predictive biomarkers are needed for personalized medicine approaches.

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...